Peptron Inc
KOSDAQ:087010
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (465.9), the stock would be worth ₩114 420.86 (55% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1 036.2 | ₩254 500 |
0%
|
| 3-Year Average | 465.9 | ₩114 420.86 |
-55%
|
| 5-Year Average | 140.2 | ₩34 425.72 |
-86%
|
| Industry Average | 10.6 | ₩2 611.14 |
-99%
|
| Country Average | 1.3 | ₩315.33 |
-100%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
P
|
Peptron Inc
KOSDAQ:087010
|
5.9T KRW | 1 036.2 | -427.9 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 361.9 | 4 278.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
197.4B USD | 4.9 | 29 | |
| US |
|
Danaher Corp
NYSE:DHR
|
137.5B USD | 6 | 36.7 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 17.9 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
35.1B CHF | 5.8 | -124.9 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
294B CNY | 5.7 | 15.4 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.5B USD | 5.1 | 26.6 | |
| US |
|
Waters Corp
NYSE:WAT
|
32.9B USD | 10.4 | 50.5 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.8B USD | 2.6 | 22.1 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27B USD | 7.1 | 30.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.6 |
| Median | 1.3 |
| 70th Percentile | 2.8 |
| Max | 96 381.4 |
Other Multiples
Peptron Inc
Glance View
Peptron Inc., a biotechnology firm based in South Korea, is weaving a narrative of innovation that marries cutting-edge research with real-world applications. Founded in 1997, the company has carved a niche in the realm of peptide-based pharmaceuticals, focusing on the formulation and delivery of these potent compounds for chronic diseases. Central to its story is the SmartDepot™ technology, a proprietary drug delivery system that ensures precise, sustained release of medication. This technology not only enhances patient compliance by reducing the frequency of dosing but also maximizes therapeutic efficacy, positioning Peptron as a trailblazer in improving patient care. At the heart of Peptron's business model is its ability to capitalize on its advanced drug delivery systems by collaborating with global pharmaceutical giants and seeking strategic partnerships. With a robust pipeline, including promising treatments for Parkinson's disease and various endocrine disorders, Peptron generates revenue through licensing deals, co-development agreements, and the eventual commercialization of its therapeutics. By balancing research innovation with savvy business collaborations, Peptron is not just navigating the competitive biotech landscape; it is rewriting the narrative on harnessing technology for transformative healthcare solutions.
